Entrectinib, a potent, CNS-active, TRK and ROS1 inhibitor is associated with occurrence of bone fractures, particularly in pediatric patients. We embarked on computer-guided and experimental investigations to identify the underlying mechanism that should help safe dosing of children receiving this drug. An artificial intelligence (AI)-based approach was used to allow for hypothesis generation regarding drug effects in a clinic...